Search
Results: 2
Synergy in anti-malarial pre-erythrocytic and transmission-blocking antibodies is achieved by reducing parasite density.
Ellie Sherrard-Smith, Katarzyna A Sala, Michael Betancourt, Leanna M Upton, Fiona Angrisano, Merribeth J Morin, Azra C Ghani, Thomas S Churcher, Andrew M Blagborough
Jan 31, 2020
Anti-malarial pre-erythrocytic vaccines (PEV) target transmission by inhibiting human infection but are currently partially protective. It has been posited, but never demonstrated, that co-administering transmission-blocking...
Anopheles stephensi Plasmodium berghei EPIDEMIOLOGY Global Health infectious disease microbiology MOUSE multigenerational population assay pre-erythrocytic vaccine synergy transmission-blocking vaccine Animals Anopheles Antibodies Blocking Antibodies Monoclonal Antibodies Protozoan Drug Synergism Female Humans Malaria Malaria Vaccines Mice Mosquito Vectors Parasite Load Plasmodium berghei Protozoan Proteins Salivary Glands Sporozoites Trophozoites
Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25.
Stephen W Scally, Brandon McLeod, Alexandre Bosch, Kazutoyo Miura, Qi Liang, Sean Carroll, Sini Reponen, Ngan Nguyen, Eldar Giladi, Sebastian Rämisch, Vidadi Yusibov, Allan Bradley, Franck Lemiale, William R Schief, Daniel Emerling, Paul Kellam, C Richter King, Jean-Philippe Julien
Oct 14, 2020
The Plasmodium falciparum Pfs25 protein (Pfs25) is a leading malaria transmission-blocking vaccine antigen. Pfs25 vaccination is intended to elicit antibodies that inhibit parasite development when ingested by Anopheles...